SAB Biotherapeutics, Inc. (SABS)Healthcare | Biotechnology | Miami Beach, United States | NasdaqCM
3.79 USD
-0.14
(-3.562%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 3.79 |
Hot Take ↕ | Aug. 22, 2026, 1:30 a.m. EDT
The investment case for SAB Biotherapeutics is currently overwhelmed by severe structural deterioration. While the balance sheet remains technically healthy with minimal debt and a fortress-like current ratio, the business has failed to generate revenue growth or profitability, posting four consecutive years of negative annual returns and a nearly 98% cumulative decline over the last four years. This multi-year trajectory suggests the market has priced out the current management team and strategy entirely. The disconnect between the 'strong buy' analyst consensus and the reality of the stock's performance is stark; analysts appear to be betting on a future catalyst that the market has already deemed insufficient to reverse the trend. Options flow confirms this pessimism, with traders aggressively buying deep out-of-the-money puts while ignoring upside potential. With no dividend to provide income and a history of eroding shareholder value, this is a speculative vehicle for high-risk turnaround bets rather than a viable investment for capital preservation or steady growth. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.058454 |
| AutoARIMA | 0.059282 |
| AutoETS | 0.066471 |
| MSTL | 0.071563 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 37% |
| H-stat | 0.27 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.140 |
| Excess Kurtosis | -1.45 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 2.389 |
| Market Cap | 344,838,336 |
| Trailing P/E | 16.48 |
| Forward P/E | -3.97 |
| Beta | 0.53 |
| Website | https://www.sab.bio |
As of Aug. 22, 2026, 1:30 a.m. EDT: Speculators are heavily positioning for downside protection, evidenced by massive open interest in out-of-the-money puts (strikes $1.00, $2.00, $3.00) across multiple expirations, particularly the Jan 2027 strike where volume vastly exceeds open interest. Conversely, call activity is negligible and concentrated near the money or slightly out-of-the-money, indicating a lack of bullish conviction despite the company's 'strong buy' analyst consensus.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.8537736 |
| Address1 | 777 W 41st St. |
| All Time High | 129.0 |
| All Time Low | 1.0 |
| Ask | 4.9 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 355,270 |
| Average Daily Volume3 Month | 681,651 |
| Average Volume | 681,651 |
| Average Volume10Days | 355,270 |
| Beta | 0.531 |
| Bid | 3.83 |
| Bid Size | 1 |
| Book Value | 2.572 |
| City | Miami Beach |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 3.79 |
| Current Ratio | 9.221 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 3.95 |
| Day Low | 3.785 |
| Debt To Equity | 2.389 |
| Display Name | SAB Biotherapeutics |
| Earnings Call Timestamp End | 1,786,019,400 |
| Earnings Call Timestamp Start | 1,786,019,400 |
| Earnings Timestamp | 1,786,019,400 |
| Earnings Timestamp End | 1,794,486,600 |
| Earnings Timestamp Start | 1,794,486,600 |
| Ebitda | -68,707,776 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -3.6 |
| Enterprise Value | 247,338,336 |
| Eps Current Year | -1.1626 |
| Eps Forward | -0.9542 |
| Eps Trailing Twelve Months | 0.23 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 3.7525 |
| Fifty Day Average Change | 0.037499905 |
| Fifty Day Average Change Percent | 0.009993312 |
| Fifty Two Week Change Percent | 85.37736 |
| Fifty Two Week High | 5.15 |
| Fifty Two Week High Change | -1.3600001 |
| Fifty Two Week High Change Percent | -0.2640777 |
| Fifty Two Week Low | 1.85 |
| Fifty Two Week Low Change | 1.9399999 |
| Fifty Two Week Low Change Percent | 1.0486486 |
| Fifty Two Week Range | 1.85 - 5.15 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,612,881,000,000 |
| Float Shares | 62,043,604 |
| Forward Eps | -0.9542 |
| Forward P E | -3.9719136 |
| Free Cashflow | -28,842,384 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 86 |
| Fullday Change | -0.14 |
| Fullday Change Percent | -3.56234 |
| Fullday Price | 3.79 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Gross Profits | -48,268,332 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0070599997 |
| Held Percent Institutions | 0.75421 |
| Implied Shares Outstanding | 90,986,368 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,704,412,800 |
| Last Split Factor | 1:10 |
| Long Business Summary | SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida. |
| Long Name | SAB Biotherapeutics, Inc. |
| Market | us_market |
| Market Cap | 344,838,336 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_268941400 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -21,787,718 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 356,666,562 |
| Number Of Analyst Opinions | 11 |
| Open | 3.91 |
| Operating Cashflow | -53,937,112 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 305 845 2813 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 3.79 |
| Post Market Time | 1,787,959,806 |
| Previous Close | 3.93 |
| Price Eps Current Year | -3.2599344 |
| Price Hint | 4 |
| Price To Book | 1.4735614 |
| Profit Margins | 0.0 |
| Quick Ratio | 8.926 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.14 |
| Regular Market Change Percent | -3.56234 |
| Regular Market Day High | 3.95 |
| Regular Market Day Low | 3.785 |
| Regular Market Day Range | 3.785 - 3.95 |
| Regular Market Open | 3.91 |
| Regular Market Previous Close | 3.93 |
| Regular Market Price | 3.79 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 202,595 |
| Return On Assets | -0.33458 |
| Return On Equity | -0.11266 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 90,986,368 |
| Shares Percent Shares Out | 0.0509 |
| Shares Short | 4,630,138 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 4,376,175 |
| Short Name | SAB Biotherapeutics, Inc. |
| Short Percent Of Float | 0.0525 |
| Short Ratio | 9.89 |
| Source Interval | 15 |
| State | FL |
| Symbol | SABS |
| Target High Price | 16.0 |
| Target Low Price | 6.0 |
| Target Mean Price | 11.63636 |
| Target Median Price | 12.0 |
| Total Cash | 102,632,000 |
| Total Cash Per Share | 1.128 |
| Total Debt | 5,132,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 0.23 |
| Trailing P E | 16.47826 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 3.807075 |
| Two Hundred Day Average Change | -0.017075062 |
| Two Hundred Day Average Change Percent | -0.0044850865 |
| Type Disp | Equity |
| Volume | 202,595 |
| Website | https://www.sab.bio |
| Zip | 33,140 |